Table 1 Baseline patient characteristics and demographic data
Vancomycin CI (n= 14) | Vancomycin II (n= 45) | p | |
|---|---|---|---|
Age, year | 60.64 (17.91) | 64.3 (13.95) | 0.417 |
Gender, male no. (%) | 9 (64.2) | 33 (73) | 0.513 |
BMI, kg/m2 | 31.08 (6.63) | 31.1(7.64) | 0.969 |
BMI > 30 kg/m2, n (%) | 6 (42.8) | 21 (46.6) | 0.803 |
Weight (kg) | 92.14 (23.39) | 91.0 (27.1) | 0.890 |
CKD baseline, n (%) | 6 (42.8) | 21 (46.6) | 0.803 |
HD baseline, n (%) | 3 (21.4) | 14 (31.1) | 0.485 |
Mechanical ventilation*, n (%) | 14 (100) | 43 (95.5) | 0.422 |
Vasopressor therapy*, n (%) | 13 (92.8) | 40 (88.8) | 0.668 |
APACHEII | 26.42 (8.01) | 32.13(7.69) | 0.019 |
SOFA score at the onset of therapy | 14.5 (2.028) | 16.5 (0.327) | 0.880 |
ICU patients, n (%) | 0.002 | ||
SICU | 13 (91.6) | 21 (46.6) | |
MICU | 1 (8.4) | 24 (53.4) | |
Albumin (g/dl) | 3.01 (0.72) | 2.86 (0.58) | 0.431 |
LOS prior to CVVH (hr) | 90.85 (114.97) | 38.58 (62.55) | 0.03 |
Hospital mortality | 7 (50) | 26 (57.7) | 0.609 |
CVVH hemofiltration rate (ml/kg/hr) | 23.75 (8.08) | 22.1 (7.7) | 0.501 |
CVVH hemofiltration rate >30 ml/kg/hr, n (%) | 4 (28.5) | 7 (15.5) | 0.275 |
CVVH duration (hr) | 262 (97.58) | 243.1 (227.4) | 0.761 |
Vancomycin start in relation to CVVH (day) | 1.39 (1.84) | 2.95 (5.62) | 0.313 |